{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:18:17Z","timestamp":1791242297637,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cpcardiol.2023.101686","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T01:53:35Z","timestamp":1678240415000},"page":"101686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Kamran","family":"Mahfooz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Najeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Naung","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Khamosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekshmi","family":"Dharmarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-6606","authenticated-orcid":false,"given":"Advait","family":"Vasavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.101686_bib0001","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0002","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","article-title":"Contribution of endogenous generation of endothelin-1 to basal vascular tone","volume":"344","author":"Haynes","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0004","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1476-5381.1995.tb13322.x","article-title":"Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type","volume":"114","author":"Davenport","year":"1995","journal-title":"British J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0005","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0006","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0007","series-title":"Hypertension: Conducting studies of drugs to treat patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry","year":"2018"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0008","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0009","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertensionassociation between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.coph.2014.12.007","article-title":"Endothelin receptors, renal effects and blood pressure","volume":"21","author":"Boesen","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IBPC.S4315","article-title":"Clinical approach in treatment of resistant hypertension","volume":"2","author":"Frank","year":"2009","journal-title":"Integr Blood Press Control"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.118.253864","article-title":"Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension","volume":"368","author":"Trensz","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0013","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/DDDT.S199051","article-title":"Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects","volume":"13","author":"Sidharta","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0015","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0016","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0017","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cpdd.815","article-title":"Effects of Multiple-dose administration of aprocitentan on the pharmacokinetics of rosuvastatin","volume":"9","author":"Sidharta","year":"2020","journal-title":"Clin Pharmacology Drug Development"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0018","doi-asserted-by":"crossref","first-page":"19067","DOI":"10.1038\/s41598-022-22470-z","article-title":"Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment","volume":"12","author":"Fontes","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0019","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cpt.2043","article-title":"Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet","volume":"109","author":"Gueneau de Mussy","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40261-019-00837-x","article-title":"Single-dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment","volume":"39","author":"Sidharta","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0021","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cpdd.881","article-title":"Multiple-dose pharmacokinetics, safety, and tolerability of aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and Caucasian subjects","volume":"10","author":"Fontes","year":"2021","journal-title":"Clin Pharmacology Drug Development"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0022","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0023","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0024","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","article-title":"Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects","volume":"85","author":"Smolander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for Overt Diabetic Nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0026","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-0083","article-title":"Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies","volume":"10","author":"Ryan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0027","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0028","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0002-9149(99)00912-1","article-title":"Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins","volume":"85","author":"S\u00fctsch","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0029","first-page":"L668","article-title":"Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs","volume":"269","author":"Sato","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/FJC.0000000000001023","article-title":"Aprocitentan (a Dual Endothelin-Receptor Antagonist) for treatment-resistant hypertension","volume":"77","author":"McCoy","year":"2021","journal-title":"J Cardiovascular Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101686_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"JAHA"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:21:29Z","timestamp":1758939689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0146280623001032"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101686","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101686"}}